Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...

Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in advanced epithelial ovarian cancer met the primary endpoint of ...

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...